tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

LEPU ScienTech Reports Strong Interim Financial Performance for 2025

Story Highlights
LEPU ScienTech Reports Strong Interim Financial Performance for 2025

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

An update from LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H ( (HK:2291) ) is now available.

LEPU ScienTech Medical Technology announced a significant increase in its financial performance for the first half of 2025, with a 32.4% rise in revenue and a 29.8% increase in net profit attributable to shareholders. Despite these gains, the company decided not to distribute an interim dividend. The company’s continued focus on innovation and expansion in the interventional medical devices sector, with numerous products in various stages of development, positions it strongly within the industry.

More about LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H

LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. is a prominent player in the interventional medical devices industry in China, focusing on the research, development, manufacture, and commercialization of heart disease interventional devices. With over 20 years of experience, the company has been advancing in degradable medical devices and exploring new areas such as heart valves and cardiac mechanical circulatory support.

Average Trading Volume: 962,272

Technical Sentiment Signal: Strong Buy

Current Market Cap: HK$9.02B

For an in-depth examination of 2291 stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1